NSGCT
MCID: NNS011
MIFTS: 26

Nonseminomatous Germ Cell Tumor (NSGCT)

Categories: Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Nonseminomatous Germ Cell Tumor

MalaCards integrated aliases for Nonseminomatous Germ Cell Tumor:

Name: Nonseminomatous Germ Cell Tumor 19 71
Non-Seminomatous Germ-Cell Tumors 19
Germ Cell Tumor, Nonseminomatous 5
Nsgct 19

Classifications:



External Ids:

UMLS 71 C1266158

Summaries for Nonseminomatous Germ Cell Tumor

GARD: 19 Nonseminomatous germ cell tumors are cancerous tumors commonly found in the pineal gland in the brain, in the mediastinum, or in the abdomen. They originate from cells that were meant to form sex cells (i.e., sperm or eggs). They are often large and have a tendency to spread more quickly than the other type of germ cell tumor (i.e., seminoma type). Possible early signs of this cancer include chest pain and breathing problems.

MalaCards based summary: Nonseminomatous Germ Cell Tumor, also known as non-seminomatous germ-cell tumors, is related to extragonadal nonseminomatous germ cell tumor and testicular germ cell tumor. An important gene associated with Nonseminomatous Germ Cell Tumor is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase). The drugs Cisplatin and Bleomycin have been mentioned in the context of this disorder. Affiliated tissues include pineal, brain and lymph node.

Related Diseases for Nonseminomatous Germ Cell Tumor

Diseases related to Nonseminomatous Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 extragonadal nonseminomatous germ cell tumor 11.6
2 testicular germ cell tumor 11.5
3 germ cell tumor 11.2
4 teratoma 10.9
5 testicular cancer 10.8
6 mature teratoma 10.7
7 embryonal carcinoma 10.6
8 germ cell cancer 10.6
9 testicular germ cell cancer 10.5
10 malignant teratoma 10.5
11 growing teratoma syndrome 10.5
12 endodermal sinus tumor 10.5
13 teratocarcinoma 10.4
14 choriocarcinoma 10.4
15 ewing sarcoma 10.4
16 mixed germ cell cancer 10.4
17 seminoma 10.4
18 mediastinal cancer 10.4
19 tatton-brown-rahman syndrome 10.3
20 respiratory failure 10.3
21 prostate cancer 10.3
22 factor vii deficiency 10.3
23 trophoblastic neoplasm 10.3
24 lymphocele 10.3
25 lung cancer 10.2
26 graves disease 1 10.2
27 mucositis 10.2
28 adult respiratory distress syndrome 10.2
29 mixed cell type cancer 10.2
30 pigmented villonodular synovitis 10.2
31 glomerulonephritis 10.2
32 tenosynovial giant cell tumor 10.2
33 pancreatic adenocarcinoma 10.2
34 liver disease 10.2
35 extragonadal germ cell cancer 10.2
36 testicular yolk sac tumor 10.2
37 spermatocytoma 10.2
38 chronic kidney disease 10.2
39 hyperthyroidism 10.2
40 renal cell carcinoma, nonpapillary 10.1
41 sarcoidosis 1 10.1
42 renal hypodysplasia/aplasia 1 10.1
43 ascites, chylous 10.1
44 chondrosarcoma 10.1
45 rhabdomyosarcoma 2 10.1
46 testicular germ cell tumor 1 10.1
47 stroke, ischemic 10.1
48 spastic paraplegia, ataxia, and mental retardation 10.1
49 sarcoidosis 2 10.1
50 sarcoidosis 3 10.1

Graphical network of the top 20 diseases related to Nonseminomatous Germ Cell Tumor:



Diseases related to Nonseminomatous Germ Cell Tumor

Symptoms & Phenotypes for Nonseminomatous Germ Cell Tumor

Drugs & Therapeutics for Nonseminomatous Germ Cell Tumor

Drugs for Nonseminomatous Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
2
Bleomycin Approved, Investigational Phase 3 9041-93-4, 11056-06-7 5360373
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Ifosfamide Approved Phase 3 3778-73-2 3690
6
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
7
Palifosfamide Investigational Phase 3 31645-39-3 100427
8 Alkylating Agents Phase 3
9 Antineoplastic Agents, Alkylating Phase 3
10 Anti-Bacterial Agents Phase 3
11 Albumin-Bound Paclitaxel Phase 3
12
Etoposide phosphate Phase 3 16760419
13 Antimitotic Agents Phase 3
14 Tubulin Modulators Phase 3
15 Antibiotics, Antitubercular Phase 3
16
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
17
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
18
Durvalumab Approved, Investigational Phase 2 1428935-60-7
19
Tremelimumab Approved, Investigational Phase 2 745013-59-6
20
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
21
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
22
Brentuximab vedotin Approved, Investigational Phase 2 914088-09-8
23
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
24 Antiviral Agents Phase 2
25 Anti-Infective Agents Phase 2
26 Antimetabolites Phase 2
27 Antirheumatic Agents Phase 2
28 Immunosuppressive Agents Phase 2
29 Immunologic Factors Phase 2
30 Antineoplastic Agents, Immunological Phase 2

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Active, not recruiting NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
2 A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors Unknown status NCT02115165 Phase 2 Cabazitaxel
3 A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis Unknown status NCT00127049 Phase 2 gemcitabine, ifosfamide, cisplatin, G-CSF
4 A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy Completed NCT02317393 Phase 2
5 A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen. Completed NCT02414685 Phase 2 Paclitaxel;Ifosfamide;Cisplatin
6 A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors Active, not recruiting NCT03158064 Phase 2 Durvalumab;Tremelimumab
7 Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT) Not yet recruiting NCT05634785 Phase 2 Cyclophosphamid;Fludarabine
8 Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring Not yet recruiting NCT05500391 Phase 2
9 A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Terminated NCT02689219 Phase 2 Brentuximab Vedotin
10 A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206 Terminated NCT02499952 Phase 2 Pembrolizumab
11 Assessment of the Utility of CT Follow Up in the Long Term Follow Up of Patients With Metastatic Non Seminomatous Germ Cell Tumour (NSGCT) Unknown status NCT00553371
12 Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology With Outcome in Early Stage Nonseminomatous Germ Cell Tumor Completed NCT00003800
13 Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials Recruiting NCT05108298 Early Phase 1

Search NIH Clinical Center for Nonseminomatous Germ Cell Tumor

Genetic Tests for Nonseminomatous Germ Cell Tumor

Anatomical Context for Nonseminomatous Germ Cell Tumor

Organs/tissues related to Nonseminomatous Germ Cell Tumor:

MalaCards : Pineal, Brain, Lymph Node, Testis, Bone Marrow, Testes, Thyroid

Publications for Nonseminomatous Germ Cell Tumor

Articles related to Nonseminomatous Germ Cell Tumor:

(show top 50) (show all 1130)
# Title Authors PMID Year
1
Codon-specific translation reprogramming promotes resistance to targeted therapy. 5
29925953 2018
2
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 5
28854169 2017
3
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 5
25079330 2014
4
Copper is required for oncogenic BRAF signalling and tumorigenesis. 5
24717435 2014
5
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 5
24670642 2014
6
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 5
24512911 2014
7
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 5
23685455 2013
8
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. 5
23302800 2013
9
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 5
22281684 2012
10
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). 5
22113612 2011
11
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 5
21107323 2010
12
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 5
21107320 2010
13
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. 5
20823850 2010
14
Inhibition of mutated, activated BRAF in metastatic melanoma. 5
20818844 2010
15
BRAF mutation in metastatic colorectal cancer. 5
19571295 2009
16
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. 5
18398503 2008
17
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 5
17785355 2007
18
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 5
17488796 2007
19
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. 5
17374713 2007
20
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 5
16772349 2006
21
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 5
16174717 2005
22
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 5
15998781 2005
23
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 5
16015629 2005
24
High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. 5
16187918 2005
25
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. 5
15687339 2005
26
Mutations of BRAF and RAS are rare events in germ cell tumours. 5
15386408 2005
27
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 5
15342696 2004
28
Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. 5
15356022 2004
29
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. 5
15181070 2004
30
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. 5
15126572 2004
31
BRAF T1796A transversion mutation in various thyroid neoplasms. 5
15001635 2004
32
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. 5
14513361 2003
33
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. 5
14602780 2003
34
Exclusion of BRAFV599E as a melanoma susceptibility mutation. 5
12794760 2003
35
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 5
12960123 2003
36
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. 5
12670889 2003
37
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. 5
12644542 2003
38
Absence of exon 15 BRAF germline mutations in familial melanoma. 5
12619120 2003
39
High frequency of BRAF mutations in nevi. 5
12447372 2003
40
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 5
12198537 2002
41
Mutations of the BRAF gene in human cancer. 5
12068308 2002
42
Role of Lactate Dehydrogenase in Identifying Relapse for Patients With Stage I Testicular Cancer on Surveillance. 62
35997696 2022
43
French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer. 62
36400478 2022
44
Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? 62
35675585 2022
45
A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor. 62
35381697 2022
46
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. 62
36379869 2022
47
Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocol. 62
36451268 2022
48
Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor? 62
36195478 2022
49
Re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor? 62
36195480 2022
50
Accuracy of germ cell tumor histology and stage within a Canadian cancer registry. 62
36218319 2022

Variations for Nonseminomatous Germ Cell Tumor

ClinVar genetic disease variations for Nonseminomatous Germ Cell Tumor:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Pathogenic
13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336

Expression for Nonseminomatous Germ Cell Tumor

Search GEO for disease gene expression data for Nonseminomatous Germ Cell Tumor.

Pathways for Nonseminomatous Germ Cell Tumor

GO Terms for Nonseminomatous Germ Cell Tumor

Sources for Nonseminomatous Germ Cell Tumor

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....